Esperion Therapeutics (ESPR) Tops Q3 EPS by 5c

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.77), $0.05 better than the analyst estimate of ($0.82).

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• BofA lists top 5 themes driving next $1tn in incremental semi sales